Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease (Q28287250)

Nature Clinical Practice Cardiovascular Medicine

Europe PubMed Central

title

Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease (English)

0 references

main subject

cardiovascular disease

1 reference

Bart Staels

1

0 references

author name string

Michel Maes

series ordinal

2

0 references

Alberto Zambon

series ordinal

3

0 references

language of work or name

English

0 references

publication date

September 2008

0 references

published in

0 references

volume

5

0 references

issue

9

0 references

page(s)

542-53

0 references

cites work

At the heart of the statin benefit

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Beyond LDL cholesterol reduction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

The paradoxical nature of hunter-gatherer diets: meat-based, yet non-atherogenic

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

The forgotten majority: unfinished business in cardiovascular risk reduction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Triglycerides and risk for coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Hypertriglyceridemia and cardiovascular risk reduction.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

HDL metabolism in hypertriglyceridemic states: an overview

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Safety considerations with fibrate therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Effects of fibrates on metabolism of statins in human hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO1278

7 January 2021